Anaptysbio (ANAB) Total Current Liabilities (2016 - 2026)

Anaptysbio has reported Total Current Liabilities for 11 years, with the latest figure at $41.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 5.3% year-over-year to $41.7 million; the trailing twelve-month figure through Mar 2026 stood at $41.7 million (down 5.3% YoY), and the FY2025 full-year result was $38.6 million, down 14.98% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $41.7 million, up from $38.6 million in the prior quarter.
• The five-year high for Total Current Liabilities was $45.4 million in Q4 2024, with the low at $19.8 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $35.3 million across 5 years, with a median of $38.1 million in 2025.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 109.51% — and 2025, when it fell 14.98%.
• Anaptysbio's Total Current Liabilities stood at $26.1 million in 2022, then surged by 43.71% to $37.4 million in 2023, then gained by 21.33% to $45.4 million in 2024, then slipped by 14.98% to $38.6 million in 2025, then grew by 7.97% to $41.7 million in 2026.
• The last three Total Current Liabilities figures came in at $41.7 million (Q1 2026), $38.6 million (Q4 2025), and $38.1 million (Q3 2025), per Business Quant data.